Scarica l'app Stockscreener
216.95
1.79%
-4.94
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Inc. $ABBV Shares Bought by Meritage Portfolio Management - MarketBeat
Why AbbVie Has Committed $100bn to US Medicine Supply Chains - Procurement Magazine
How AbbVie’s $100bn Investment Reshapes Pharma Supply Chains - Supply Chain Digital Magazine
AbbVie’s US$100bn Deal Could Transform US Healthcare Access - Healthcare Digital
Conning Inc. Decreases Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly - Stocktwits
AbbVie: stepping up obesity treatments with an alternative approach to GLP-1 - marketscreener.com
Rep. Julia Letlow Sells Off Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie stock in focus after hours as it eyes obesity market — what to watch next - TechStock²
Top Research Reports for AbbVie, Intel & Boeing - Yahoo Finance
AbbVie plans to build out its presence in obesity market - Reuters
AbbVie Reaches Agreement With Trump Administration, Joining MFN Initiatives - Pharmacy Times
AbbVie to invest $100 billion in the U.S in exchange for tariff exemptions - The American Bazaar
JP Morgan 2026: AbbVie Advances its Pipeline - PharmExec.com
Key facts: AbbVie Reports Growth in Immunology, Neuroscience; Targets Weight-Loss Market - TradingView — Track All Markets
AbbVie sets sights on immunology, neurology dominance - Crain's Chicago Business
AbbVie Bets Big on Chinese Cancer Drug in $5.6 Billion Licensing Deal - Caixin Global
AbbVie Joins TrumpRx in Exchange for Tariff Relief and Pricing Flexibility - Pharmaceutical Commerce
AbbVie (ABBV) Rises on Agreement for Drug Pricing and Investment Commitment - GuruFocus
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy? - Yahoo Finance
Stephens Inc. AR Boosts Position in AbbVie Inc. $ABBV - MarketBeat
Retirement Planning Group LLC Buys 6,958 Shares of AbbVie Inc. $ABBV - MarketBeat
Kera Capital Partners Inc. Makes New Investment in AbbVie Inc. $ABBV - MarketBeat
AbbVie’s Trump Deal Unlocks US$100bn for R&D & Manufacturing - Manufacturing Digital
Robeco Schweiz AG Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie To Buy Device Manufacturing Facility From West Pharmaceutical Services - Med Device Online
AbbVie inks USD 5.6bn global licensing deal with Chinese biotech for cancer therapy - medwatch.com
AbbVie strikes deal with Trump, pledges USD 100bn investment over 10 years - medwatch.com
Trump administration strikes deal with AbbVie to cut costs of certain drugs - KCRA
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - Stocktwits
Key facts: AbbVie signs Medicaid deal; banker charged with insider trading; UAE launches mental health campaign - TradingView — Track All Markets
AbbVie and Trump administration reach agreement on drug prices, tariffs - Daily Herald
AbbVie news: Trump administration strikes deal with North Chicago-based company to cut costs of certain drugs - ABC7 Chicago
Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight - GlobeNewswire Inc.
AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions - TradingView — Track All Markets
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon - TradingView — Track All Markets
Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings? - The Globe and Mail
AbbVie, RemeGen Partner on Novel Bispecific Antibody for Advanced Tumors - Contract Pharma
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know - Yahoo Finance
AbbVie’s $100 Billion Gamble: A Strategic Trade With Washington to Lower Drug Costs - abacusnews.com
AbbVie Secures Tariff Relief Pact - GuruFocus
AbbVie pledges $100B to US production in drug pricing deal with Trump - BioPharma Dive
AbbVie and China’s RemeGen kick off year with $5.6bn oncology deal - BioXconomy
Polaris Capital Management LLC Cuts Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Commits $100B in US R&D, Manufacturing, Winning Tariff, Pricing Exemptions - BioSpace
AbbVie reaches 3-year deal with White House to lower drug prices - MSN
Nordea Investment Management AB Raises Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie inks MFN drug pricing deal, pledges $100bn to US R&D - Pharmaceutical Technology
AbbVie adds Arizona plant to $10bn US manufacturing push - The Pharma Letter
Abbvie, US reach agreement to cut drug prices - WHTC
AbbVie Stock Rises After $100 Billion Deal With Trump. It Will Avoid Tariffs. - Barron's
ZAWYA-PRESSR: Ministry of Health and Prevention launches "Mental Health 360" campaign in collaboration with AbbVie - TradingView — Track All Markets
Remegen stock rating upgraded by JPMorgan on AbbVie licensing deal - Investing.com Canada
AbbVie reaches deal with Trump administration on drug prices in exchange for tariff relief - Yahoo Finance
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules - BioSpace
AbbVie (ABBV) Strikes $100 Billion Deal with Trump Administratio - GuruFocus
AbbVie secures tariff relief in drug pricing deal, pledges $100B investment (ABBV:NYSE) - Seeking Alpha
AbbVie pledges $100 billion U.S. investment to avoid tariffs - Crain's Chicago Business
AbbVie Pledges $100 Billion US Investment to Avoid Tariffs - Bloomberg.com
AbbVie Puts Up $650M to Join Emerging But Crowded Area of Cancer Drug R&D - MedCity News
AbbVie to cut drug prices, pledges $100 billion for research - marketscreener.com
2.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):